Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
S-65487 by Les Laboratoires Servier for Marginal Zone B-cell Lymphoma: Likelihood of Approval
S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Marginal Zone B-cell Lymphoma. According...
S-65487 by Les Laboratoires Servier for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Relapsed Acute Myeloid Leukemia. According...
S-65487 by Les Laboratoires Servier for Refractory Acute Myeloid Leukemia: Likelihood of Approval
S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Refractory Acute Myeloid Leukemia. According...
S-65487 by Les Laboratoires Servier for Refractory Multiple Myeloma: Likelihood of Approval
S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Refractory Multiple Myeloma. According to...
S-65487 by Les Laboratoires Servier for Relapsed Multiple Myeloma: Likelihood of Approval
S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Relapsed Multiple Myeloma. According to...
S-65487 by Les Laboratoires Servier for Follicular Lymphoma: Likelihood of Approval
S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Follicular Lymphoma. According to GlobalData,...
S-65487 by Les Laboratoires Servier for Mantle Cell Lymphoma: Likelihood of Approval
S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Mantle Cell Lymphoma. According to...
S-65487 by Les Laboratoires Servier for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...
S-65487 by Les Laboratoires Servier for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...